Relating to labeling requirements for compounded drug products.
Impact
If enacted, HB3785 will amend the Occupations Code to introduce Section 562.157, which outlines these labeling requirements. This move is significant as it seeks to address past concerns regarding the safety and efficacy of compounded drugs, especially following incidents that raised awareness about quality control in compounding pharmacies. The bill specifies that the labeling must be clear and informative to both patients and pharmacists, thereby improving the overall standard of care in the pharmacy sector across Texas.
Summary
House Bill 3785 focuses on establishing detailed labeling requirements for compounded drug products. Compounded drugs are those that are mixed or altered by pharmacists to meet the specific needs of patients. The bill aims to enhance the safety and transparency of these products by mandating that pharmacies provide comprehensive information on drug labels. This includes the name and contact details of the pharmacy, active ingredients, dosage instructions, and potential side effects, among other information. It is hoped that these requirements will inform patients better and contribute to their safety when receiving compounded medications.
Contention
While the bill appears to have strong support due to its focus on drug safety, there may be concerns among pharmacists about the feasibility of implementing these comprehensive labeling requirements. Some practitioners may argue that overly detailed labeling could complicate their processes or overwhelm patients with information. Additionally, discussions around the additional regulatory burden could surface, particularly regarding how it impacts smaller pharmacies that may struggle with compliance costs relative to larger chains.
Implementation
The Texas State Board of Pharmacy is tasked with adopting these new rules, with a deadline set for December 1, 2025. The bill is scheduled to take effect on September 1, 2025, providing a timeline for pharmacies to prepare for compliance. This demonstrates a legislated balance between making necessary regulatory adjustments and allowing pharmacies adequate time to adapt to new standards.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023 This bill relaxes certain requirements for compounding drugs that are facing shortages. Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally, a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements. This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for an urgent medical need not involving a specific patient if, among other requirements (1) the prescriber certifies that the prescriber is unable, despite reasonable attempts, to obtain certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug. Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists.
A BILL to amend and reenact §§ 54.1-3406 and 54.1-3410.2 of the Code of Virginia, relating to Board of Pharmacy; compounding pharmacies; use of bulk drug substances; recordkeeping.
Prohibiting the transfer of hemp-derived cannabinoid products to any person under the age of 21, establishing packaging and labeling requirements for such products and amending the definition of industrial hemp and hemp products.
A BILL to amend and reenact §§ 54.1-3406 and 54.1-3410.2 of the Code of Virginia, relating to Board of Pharmacy; compounding pharmacies; use of bulk drug substances; recordkeeping.